BioCentury
ARTICLE | Company News

Management tracks: Maze, Tiaki, NED, Annexon and more

July 10, 2019 10:58 PM UTC

Maze Therapeutics (Redwood City, Calif.) said Richard Scheller joined its board. Scheller, who in January became chairman of R&D at BridgeBio Pharma Inc. (NASDAQ:BBIO), was CSO and head of therapeutics at personal genetics company 23andMe Inc. (Mountain View, Calif.) from 2015 to 2019, according to a regulatory filing. Prior to that, he was head of Genentech Inc.’s research and early development (gRED) unit. Maze develops genetic modifier therapies for genetically defined diseases (see “Navigating Third Rock’s Maze”).

Tiaki Therapeutics (Cambridge, Mass.) hired Suzanne Bruhn as president and CEO. She succeeds interim CEO Barbara Tate, chief strategy officer of the Dementia Discovery Fund, which founded Tiaki. Bruhn was president and CEO of Proclara Biosciences Inc. (Cambridge, Mass.). Tiaki is developing therapeutics that target microglia to treat inflammatory-driven CNS disorders...